Early PKD Observational Cohort Study

Description

This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested.

Conditions

Polycystic Kidney Disease

Study Overview

Study Details

Study overview

This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested.

Early PKD Observational Cohort Study

Early PKD Observational Cohort Study

Condition
Polycystic Kidney Disease
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago, Chicago, Illinois, United States, 60637

Kansas City

University of Kansas Medical Center, Kansas City, Kansas, United States, 66160

Kansas City

Children's Mercy Hospital, Kansas City, Missouri, United States, 64108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Inclusion for early stage autosomal dominant polycystic kidney disease (ADPKD):
  • * Family history of PKD
  • * All races and ethnic groups
  • * Glomerular filtration rate (GFR) \>80 ml/min per 1.73 m2
  • * Inclusion for Healthy Volunteers:
  • * Male or female with no family history of kidney disease
  • * All races and ethnic groups
  • * Normal GFR
  • * Non-insulin or insulin-dependent diabetes mellitus
  • * Systemic illness (i.e.systemic lupus erythematosus, vasculitis)
  • * Unable to provide written informed consent
  • * Unavailable for magnetic resonance imaging (MRI) and blood/urine collection

Ages Eligible for Study

4 Years to 35 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Kansas Medical Center,

Alan SL Yu, MD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Darren P Wallace, PhD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Study Record Dates

2025-06